Search
Recently, Tirzepatide, a groundbreaking medication developed by Eli Lilly and Company, has been incorporated into the latest edition of the National Reimbursement Drug List. This move has significantly reduced prices for antidiabetic and weight-loss drugs in the domestic market. Before the official rollout of Tirzepatide's medical insurance-covered price, certain online pharmacies have already commenced pre-sales at discounted rates. According to the Meituan Medicine Purchase platform, the pre-sale price for the 10mg dose of Tirzepatide has dropped to a mere 450 yuan, representing roughly 20% of its previous price tag. Moreover, prices for other GLP-1 receptor agonist drugs, such as Semaglutide, have also seen adjustments online, signaling the initial effects of medical insurance policies on pricing in the non-hospital retail sector.
-
C114 Communication Network -
Communication Home
